EWA
CCCC icon

EverSource Wealth Advisors’s C4 Therapeutics CCCC Stock Holding History

EverSource Wealth Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-310
Closed -$444 – 4345
2025
Q2 		$444 Buy
310
+277
+839% +$403 ﹤0.01% 3923
2025
Q1 		$53 Buy
33
+29
+725% +$86 ﹤0.01% 3894
2024
Q4 		$14 Buy
+4
New +$20 ﹤0.01% 3724
2023
Q4 		– Sell
-448
Closed -$833 – 2652
2023
Q3 		$833 Buy
+448
New +$1.37K ﹤0.01% 2291

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EverSource Wealth Advisors's CCCC Position: Q3 2025 in Review

EverSource Wealth Advisors sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 310 shares — an estimated $444 sold.

EverSource Wealth Advisors first reported a position in CCCC in Q3 2023 and held it in 4 quarters. The position peaked at $833 in Q3 2023. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • EverSource Wealth Advisors reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 310 C4 Therapeutics shares in Q3 2025, an estimated $444.
  • EverSource Wealth Advisors first reported a position in C4 Therapeutics in Q3 2023 and held it in 4 quarters.
  • EverSource Wealth Advisors's C4 Therapeutics position peaked at $833 in Q3 2023.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on EverSource Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.